Skip to main content
. Author manuscript; available in PMC: 2012 Dec 27.
Published in final edited form as: Bioorg Med Chem. 2010 Jun 18;18(15):5576–5592. doi: 10.1016/j.bmc.2010.06.038

Figure 1.

Figure 1

Proteasome inhibitors; Bortezomib (clinically approved covalent and reversible inhibitor). CEP- 18770 (reversible inhibitor), carfilzomib and salinosporamide A (irreversible inhibitors) currently in phase I and II clinical trials. PI-083 (reversible inhibitor identified from the NCI diversity set-1).